




World Health
Organization

Taenia solium

Use of existing diagnostic tools in public health programmes

Report of a virtual meeting of experts, 17 May 2022





World Health
Organization

Taenia solium

Use of existing diagnostic tools in public health programmes

Report of a virtual meeting of experts, 17 May 2022

Taenia solium - use of existing diagnostic tools in public health programmes: report of a virtual meeting of experts, 17 May 2022

ISBN 978-92-4-006072-2 (electronic version)

ISBN 978-92-4-006073-9 (print version)

© **World Health Organization 2022**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. *Taenia solium* - use of existing diagnostic tools in public health programmes: report of a virtual meeting of experts, 17 May 2022. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Contents

1. Meeting objectives.....	1
2. Background.....	1
3. Methodology	2
4. Meeting conclusions and next steps	3
5. Future considerations	7
5.1 Diagnostics development	7
5.2 Laboratory capacity.....	7
5.3 Training requirements	7
5.4 Operational research.....	7
5.5 One Health.....	7
References	8
Annex. List of participants	9



1. Meeting objectives

The World Health Organization (WHO) convened a virtual meeting of experts on 17 May 2022 to review existing diagnostic tools for *Taenia solium*, which can be used to provide evidence to support the decision to implement public health programmes to control diseases caused by *T. solium*. The participants are listed in the Annex. All invited experts and observers completed the WHO conflict of interest and confidentiality forms. No conflicts were identified. The outcome of this review will inform the development of a *T. solium* monitoring and evaluation framework.

The specific meeting objectives were:

1. To evaluate the key characteristics (sensitivity, specificity, commercial availability and affordability) of the existing diagnostic tools for *T. solium* in both humans and pigs that could be used to determine whether infection prevalence exceeds a defined threshold in population-based surveys;
2. To describe the usefulness of the tools for mapping and monitoring, with consideration for survey setting, age group and sample size; and
3. To identify immediate priorities for *T. solium* test development for public health programmes.




2. Background

Taeniasis and cysticercosis caused by the parasite *T. solium* affect vulnerable populations, mainly in Latin America, sub-Saharan Africa and Asia, where pigs (the intermediate host) roam free and poor sanitation allows pigs access to human faeces.

Human taeniasis is usually asymptomatic, but cysticercosis can lead to neurocysticercosis, which manifests as seizures and epilepsy, and can be fatal (Fig. 1). Pigs usually do not show any clinical signs of infection, but heavily infected pigs can harbour larval cysts in their tongues.

Taeniasis and cysticercosis were added to WHO's list of neglected tropical diseases in 2010. Since then, progress in controlling the diseases has been slow, mainly due to a lack of adequate diagnostics, control tools and knowledge. Recently, however, new tools and guidance have become available including the Bayer donation of taenicial medicines (praziquantel and niclosamide), the Pan American Health Organization/WHO *Guidelines for preventive chemotherapy to for the control of T. solium taeniasis* (1), the WHO *Guidelines on management of T. solium neurocysticercosis* (2), the commercial availability of the TSOL18 vaccine (and its inclusion in the World Organisation for Animal Health Terrestrial Manual (3)) and the use of the vaccine in conjunction with oxfendazole in pigs, as well as results from an increasing number of field studies evaluating control interventions.

Figure 1. *T. solium* transmission cycle



Several countries are ready to begin implementation of public health programmes for the control of *T. solium* and are requesting WHO to provide specific guidance on which diagnostic tools should be used and overall guidance on monitoring and evaluation. Currently, there is inadequate evidence available to support the development of formal WHO guidelines; however, there is an urgent need to provide interim guidance to countries. Therefore, the conclusions outlined below are meant to fill this urgent need and serve as the basis for generating evidence that can be used to support more formal WHO recommendations.



3. Methodology

Technical experts in *T. solium* were requested to provide information and supporting evidence related to the performance and feasibility of existing *T. solium* diagnostic tests in humans or pigs. The aim was to understand the potential use of these tests to support mapping and programme monitoring. A literature review, peer-reviewed publications, and unpublished data were assembled by the experts as background to the meeting. Experts were requested to provide inputs on ease of use, commercial availability and affordability in low- and middle-income countries. The responses were compiled by the secretariat, summarized and circulated before the meeting on 17 May 2022. During the virtual meeting, the compiled evidence and information were reviewed by the experts. This report provides conclusions, next steps and future considerations for the use of identified diagnostic tests to support public health programmes.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31888

